Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FULC
FULC logo

FULC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Fulcrum Therapeutics Inc (FULC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.040
1 Day change
-52.57%
52 Week Range
15.740
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

FULC is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a modestly constructive short-term technical setup, but the longer-term trend is still weak and there is no recent news or clear fundamental catalyst to justify an immediate buy. The best direct read is to hold off for now rather than buy aggressively at current levels.

Technical Analysis

FULC closed at 6.82, essentially unchanged on the day. Momentum is mixed: MACD histogram is positive and expanding, which supports short-term strength, and RSI_6 at 56.7 is neutral to slightly bullish. However, the moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which signals the broader trend is still weak. Price is sitting above the pivot at 6.589 and below resistance at 7.139, so near-term upside exists, but the long-term trend does not yet confirm a durable breakout. The stock trend model also suggests only modest next-day, next-week, and next-month upside.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is bullish on balance. The very low open interest put-call ratio of 0.19 indicates far more call interest than put interest, and the put-call volume ratio of 2.0 shows elevated put volume today, which can reflect hedging or short-term caution. Call open interest is much larger than put open interest, and implied volatility is high at 107.15, showing the market expects meaningful movement. Overall, options lean bullish but with some defensive activity mixed in.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
4

Positive Catalysts

  • ["BofA raised its price target to $8 from $7, showing a slightly improved valuation view.", "MACD is positive and expanding, indicating improving near-term momentum.", "Options positioning shows strong call-heavy open interest, which can support bullish sentiment.", "The stock is trading above the pivot level at 6.589, leaving room toward near-term resistance."]

Neutral/Negative Catalysts

  • ["BofA still keeps an Underperform rating, so the broader analyst stance remains negative.", "No news in the past week means there is no fresh event-driven catalyst.", "Moving averages remain bearish, with SMA_200 above shorter averages.", "Hedge fund and insider activity are both neutral, offering no supportive accumulation signal.", "No recent congress trading data or influential buying support was reported."]

Financial Performance

Latest quarter financials were not available due to a reporting error, so there is no usable quarterly revenue or earnings snapshot to evaluate growth trends. That limits confidence in a long-term buy decision, especially for a beginner investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst action was mildly positive on price target but still negative on rating: BofA lifted its target to $8 from $7 while maintaining an Underperform rating after the Q1 report. This means Wall Street sees slightly better value than before, but the overall pros view remains cautious to bearish rather than bullish.

Wall Street analysts forecast FULC stock price to rise
11 Analyst Rating
Wall Street analysts forecast FULC stock price to rise
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 6.420
sliders
Low
7
Averages
16.8
High
25
Current: 6.420
sliders
Low
7
Averages
16.8
High
25
BofA
Underperform
downgrade
$8 -> $3
AI Analysis
2026-06-02
New
Reason
BofA
Price Target
$8 -> $3
AI Analysis
2026-06-02
New
downgrade
Underperform
Reason
BofA lowered the firm's price target on Fulcrum Therapeutics to $3 from $8 and keeps an Underperform rating on the shares after the company announced the discontinuation of pociredir in sickle cell disease following feedback from FDA on malignancy risk. The firm, which notes that tazemetostat, another PRC2 inhibitor approved in cancer indications was recently withdrawn from the market following elevated rates of hematological malignancies in treated patients, removed value for pociredir in sickle cell disease from its model.
Leerink
Outperform
to
Market Perform
downgrade
$24 -> $4
2026-06-02
New
Reason
Leerink
Price Target
$24 -> $4
2026-06-02
New
downgrade
Outperform
to
Market Perform
Reason
Leerink downgraded Fulcrum Therapeutics to Market Perform from Outperform with a price target of $4, down from $24, after the company announced the discontinuation of the pociredir program in sickle cell disease, driven primarily by FDA's concerns surrounding the broader polycomb repressive complex 2 inhibitor class and the potential risk of secondary malignancies. While "surprised by this outcome," the firm sees limited visibility into future value creation beyond strategic alternatives and cost-cutting initiatives, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FULC
Unlock Now

People Also Watch